The global transfection reagent and equipment market revenue is expected to register a moderate CAGR over the forecast period. The global transfection reagent and equipment market report has been segmented on the basis of product, method, application, and region.

On the basis of product, the global transfection reagent and equipment market has been segmented into reagents and instruments. The instruments segment is expected to register fastest growth rate over the forecast period.

On the basis of method, the global transfection reagent and equipment market has been segmented into biochemical methods, physical methods, and viral methods. The biochemical segment is expected to account major revenue share over the forecast period.

On the basis of application, the global transfection reagent and equipment market has been segmented into biomedical research, protein production, and therapeutic delivery. The biomedical research segment is estimated to account for major revenue share over the forecast period. Increasing government funding for research and development of cancer, owing to rapidly increasing incidence of cancer is a major factor expected to boost growth of the segment over the forecast period.

Request for the Sample Report Here: https://marketresearch.biz/report/transfection-reagent-and-equipment-market/request-sample/

On the basis of region, the global transfection reagent and equipment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America market is projected to hold significant revenue share in the global transfection reagent and equipment market in 2017. This is attributed to the increasing bio-based drug research in the region. Asia Pacific transfection reagent and equipment market has been anticipated to register highest CAGR in terms of revenue in next ten years, owing to the rapidly growing pharmaceutical and biotechnology industries in the region.

Key players operating in the global transfection reagent and equipment market include Thermo Fisher Scientific Inc., Promega Corporation, F. Hoffmann-La Roche Ltd., Bio–Rad Laboratories, Inc., Maxcyte, Inc., Lonza Group Ltd., Merck KGaA, Polyplus-Transfection SA, Mirus Bio LLC., and OriGene Technologies Inc.